Form 4: OptimizeRx CFO/COO Edward Stelmakh Reports Stock Transactions
SEC Form 4 Filing
Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the vesting and subsequent tax withholding of shares.
Summary
- Edward Stelmakh, the CFO/COO of OptimizeRx Corp, filed a Form 4 detailing changes in beneficial ownership.
- On October 11, 2024, 8,222 restricted stock units vested and converted into common stock.
- 2,066 shares were withheld by the issuer to cover the reporting person's tax obligations at a price of $6.63 per share.
- Following these transactions, Stelmakh directly owns 33,366 shares of OptimizeRx Corp.
- The filing clarifies that it should not be construed as an admission of beneficial ownership or a legal requirement to file the statement.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing reflecting standard compensation practices; therefore, the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of compliance for corporate insiders and provide transparency into their transactions in company stock.
Stakeholder Impact
- The transactions have a minor dilutive effect on existing shareholders due to the issuance of shares from vested RSUs.
- The tax withholding ensures compliance with tax regulations.
Key Dates
| Date | Description |
|---|---|
| October 11, 2022 | First anniversary of the grant date for restricted stock units. |
| October 11, 2024 | Date of restricted stock units vesting and tax withholding. |
| October 15, 2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.